Micro
Developing
Active
Eli Lilly espande l'accesso a Zepbound per la crescita a lungo termine
Punteggio
0,5
Velocità
▲ 0,0
Articoli
9
Fonti
4
Riepilogo
Un articolo appartiene a questa narrazione se discute l'espansione dell'accesso a Zepbound da parte di Eli Lilly e le sue prospettive di crescita a lungo termine.
Articoli Correlati
Jim Cramer Likes Eli Lilly’s (LLY) New Deal
Yahoo Finance
·
Apr 05, 2026
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
Nasdaq
·
Apr 04, 2026
Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know
CNBC
·
Apr 01, 2026
The cutthroat battle for the US weight-loss drug market
BBC Business
·
Mar 23, 2026
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook
Yahoo Finance
·
Mar 22, 2026
Fonti
Jim Cramer Likes Eli Lilly’s (LLY) New Deal
Yahoo Finance
Is Eli Lilly and Company (LLY) The Best Pharma Stock …
Yahoo Finance
Cronologia
Ultimo aggiornamento
Mar 22, 2026